Page 141 - 《中国药房》2024年12期

Diabetes Obes Metab，2022，24（1）：94-105. cemia and alpha- and beta-cell function and reduces en‐
[ 4 ] GORGOJO-MARTÍNEZ J J，MEZQUITA-RAYA P， dogenous glucose release in patients with type 2 diabetes
CARRETERO-GÓMEZ J，et al. Clinical recommenda‐ [J]. Diabetes，2004，53（5）：1187-1194.
tions to manage gastrointestinal adverse events in patients [16] VAN BLOEMENDAAL L，TEN KULVE J S，LA FLEUR
treated with GLP-1 receptor agonists：a multidisciplinary S E，et al. Effects of glucagon-like peptide 1 on appetite
expert consensus[J]. J Clin Med，2022，12（1）：145. and body weight：focus on the CNS[J]. J Endocrinol，
[ 5 ] SODHI M，REZAEIANZADEH R，KEZOUH A，et al. 2014，221（1）：T1-T16.
Risk of gastrointestinal adverse events associated with [17] NAUCK M A，QUAST D R，WEFERS J，et al. GLP-1 re‐
glucagon-like peptide-1 receptor agonists for weight loss ceptor agonists in the treatment of type 2 diabetes：state-
[J]. JAMA，2023，330（18）：1795-1797. of-the-art[J]. Mol Metab，2021，46：101102.
[ 6 ] HOLST J J. The physiology of glucagon-like peptide 1[J]. [18] SMITS M M，VAN RAALTE D H. Safety of semaglutide
Physiol Rev，2007，87（4）：1409-1439. [J]. Front Endocrinol，2021，12：645563.
[ 7 ] JASTREBOFF A M，ARONNE L J，AHMAD N N，et al. [19] O’NEIL P M，BIRKENFELD A L，MCGOWAN B，et al.
Tirzepatide once weekly for the treatment of obesity[J]. N Efficacy and safety of semaglutide compared with liraglu‐
Engl J Med，2022，387（3）：205-216. tide and placebo for weight loss in patients with obesity：a
[ 8 ] ANDERSEN A，KNOP F K，VILSBØLL T. A pharmaco‐ randomised，double-blind，placebo and active controlled，
logical and clinical overview of oral semaglutide for the dose-ranging，phase 2 trial[J]. Lancet，2018，392（10148）：
treatment of type 2 diabetes[J]. Drugs，2021，81（9）：1003- 637-649.
1030. [20] NAUCK M A，MEIER J J. Management of endocrine
[ 9 ] MEIER J J. Efficacy of semaglutide in a subcutaneous and disease：are all GLP-1 agonists equal in the treatment of
an oral formulation[J]. Front Endocrinol，2021，12： type 2 diabetes? [J]. Eur J Endocrinol，2019，181（6）：
645617. R211-R234.
[10] LINNEBJERG H，PARK S，KOTHARE P A，et al. Effect [21] BELLIDO D，ABELLÁN P，RUIZ PALOMAR J M，et al.
of exenatide on gastric emptying and relationship to post‐ Intensification of basal insulin therapy with lixisenatide in
prandial glycemia in type 2 diabetes[J]. Regul Pept，2008， patients with type 2 diabetes in a real-world setting：the
151（1/2/3）：123-129. BASAL-LIXI study[J]. Curr Ther Res Clin Exp，2018，89：
[11] JUHL C B，HOLLINGDAL M，STURIS J，et al. Bedtime 37-42.
administration of NN2211，a long-acting GLP-1 deriva‐ [22] WADDEN T A，BAILEY T S，BILLINGS L K，et al. Ef‐
tive，substantially reduces fasting and postprandial glyce‐ fect of subcutaneous semaglutide vs placebo as an adjunct
mia in type 2 diabetes[J]. Diabetes，2002，51（2）：424-429. to intensive behavioral therapy on body weight in adults
[12] RAYNER C K，SAMSOM M，JONES K L，et al. Relation‐ with overweight or obesity：the STEP 3 randomized clini‐
ships of upper gastrointestinal motor and sensory function cal trial[J]. JAMA，2021，325（14）：1403-1413.
with glycemic control[J]. Diabetes Care，2001，24（2）： [23] GUDIN B，LADHARI C，ROBIN P，et al. Incretin-based
371-381. drugs and intestinal obstruction：a pharmacovigilance
[13] SMITS M M，TONNEIJCK L，MUSKIET M H，et al. Ga- study[J]. Therapie，2020，75（6）：641-647.
strointestinal actions of glucagon-like peptide-1-based [24] KALAS M A，GALURA G M，MCCALLUM R W.
therapies：glycaemic control beyond the pancreas[J]. Dia‐ Medication-induced gastroparesis：a case report[J]. J In‐
betes Obes Metab，2016，18（3）：224-235. vestig Med High Impact Case Rep， 2021， 9：
[14] THAZHATH S S，MARATHE C S，WU T Z，et al. The 23247096211051919.
glucagon-like peptide 1 receptor agonist exenatide inhibits [25] HOROWITZ M，ARODA V R，HAN J，et al. Upper and/
small intestinal motility，flow，transit，and absorption of or lower gastrointestinal adverse events with glucagon-
glucose in healthy subjects and patients with type 2 diabe‐ like peptide-1 receptor agonists：incidence and conse‐
tes：a randomized controlled trial[J]. Diabetes，2016，65 quences[J]. Diabetes Obes Metab，2017，19（5）：672-681.
（1）：269-275. [26] KANOSKI S E，RUPPRECHT L E，FORTIN S M，et al.
[15] DEGN K B，JUHL C B，STURIS J，et al. One week’s The role of nausea in food intake and body weight sup‐
treatment with the long-acting glucagon-like peptide 1 de‐ pression by peripheral GLP-1 receptor agonists，exendin-4
rivative liraglutide（NN2211）markedly improves 24 h gly‐ and liraglutide[J]. Neuropharmacology，2012，62（5/6）：

中国药房 2024年第35卷第12期 China Pharmacy 2024 Vol. 35 No. 12 · 1543 ·